STOCK SURGE DAILY
with Ross Givens
Home » Weekly Stock Picks » Watchlist week of Oct 11, 2021

Watchlist week of Oct 11, 2021

Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on reddit
Reddit
Share on email
Email

Entravision Communications Corporation

Entravision Communications Corporation (EVC) is a Santa Monica, California-based broadcasting and communication services company. The company operates television, radio and digital business segments, with 54 television stations and 48 Spanish-language radio stations.

It also offers digital advertising solutions and operates Entravision Solutions, which sells ads and syndicate radio programming.

Here’s how the chart is setting up:

Daily Chart of Entravision Communications Corporation (EVC) — Source: TradingView

And here’s how the stock is setting up with my Stock Surge Indicator (SSI):

  • Surge score: 98/100
  • % Above 52-wk low: 331%
  • MFI reading: 58
  • Sales growth: +295%
  • Triple momentum: yes

From a technical perspective, EVC has made a series of higher highs and higher lows for the last five months.

The stock is up big, and traders finally have a low risk point from which to enter.

Sales and earnings have grown by triple digits in each of the last three quarters, and analysts are projecting further growth through 2022.

A pivot has formed at $7.73. And I’ll be using the Sept. 29 low as a stop.

Candel Therapeutics, Inc.

Candel Therapeutics, Inc. (CADL), formerly known as Advantagene, Inc., is a clinical-stage biopharmaceutical company that focuses on developing and commercializing cancer immunotherapy drugs.

Its product pipeline currently includes drugs for the treatment of prostate and pancreatic cancers as well as those that specifically target tumor cells while minimizing harmful effects on healthy tissue.

Here’s how the chart is setting up:

Daily Chart of Candel Therapeutics, Inc. (CADL) — Source: TradingView

And here’s how the stock is setting up with my SSI:

  • Surge score: 93/100
  • % Above 52-wk low: 92.4%
  • MFI reading: 70
  • Sales growth: +0%
  • Triple momentum: N/A

Candel is a recent initial public offering (IPO) forming its first base.

As an early-stage biotech, CADL has no sales or earnings to evaluate, so we are putting a large emphasis on the price action.

IPOs have been hot this year. Several have delivered huge gains in the opening weeks and months, and Candel could easily be the next big winner.

The entry and exit points noted on the chart represent my maximum risk of 10% risk on the trade.

However, if you want to give it a little more room, you could work a stop beneath last Monday’s low at $9.40.

Houghton Mifflin Harcourt Company

Houghton Mifflin Harcourt Company (HMHC) is the Boston, Massachusetts-based learning company that was founded all the way back in 1832.

It offers educational products like textbooks and digital courseware as well as printed and digital fiction and non-fiction consumer books, dictionaries and reference works to schools, libraries and businesses.

Here’s how the chart is setting up:

Daily Chart of Houghton Mifflin Harcourt Company (HMHC) — Source: TradingView

And here’s how the stock is setting up with my SSI:

  • Surge score: 99/100
  • % Above 52-wk low: 551%
  • MFI reading: 64
  • Sales growth: +43%
  • Triple momentum: yes

With a Surge Score of 99/100, HMHC is the Lamborghini of stocks. It is in the elite top 1% of stocks outperforming all others in the market.

After an earnings gap higher in early August, shares have been consolidating in the textbook compression pattern with clear resistance.

Note the volume over the last two weeks. Down days saw very little volume while positive days experienced much higher volume.

This is a good sign, as it is likely indicative of further institutional accumulation. In other words, the big players are still buying it.

I will be looking to buy HMHC on a breakout to new high ground.

Embrace the Surge,

Ross Givens
Ross Givens

I bought my first stock when I was 12 years old. It was Microsoft. I’ve been a registered financial advisor. I’ve worked as a stock broker. I ran a managed fund. I was a Vice President at JP Morgan with Series 7, Series 66 and Series 3 securities licenses. I’ve been featured on Fox Business, CNBC, Bloomberg, and a bunch of other networks. The only thing I enjoy more than making money, is helping YOU make money.

guest
0 Comments
Inline Feedbacks
View all comments

Whats in the Article

STOCK SURGE DAILY
With Ross Givens

Looking for an edge? Ross has the inside scoop on top analysis that will help grow your portfolio.. Receive a new stock opportunity every day and get ready to see your investment SURGE!

var _avp = _avp || []; if (!document.cookie || document.cookie.indexOf('AVPDCAP=') == -1) { _avp.push({ tagid: 'yG3QYYxR6xQIhwBD9CEg', alias: '/', type: 'dynamic', zid: 45, pid: 0, secure: true }); }

Wanna learn how to flip losing trades into winners?

Enter Email Below For Instructions

This will expire soon, act now!